StemVacs Cancer Platform

An immuno-oncology cellular therapy that programs the immune system to selectively attack malignant cells.

 

The overarching approach to cancer on the StemVacs Platform is as follows:

  1. Treat innate immune suppression: Administration of oral NanoStilbene to decrease immune suppressive toxic molecules made by tumor and tumor microenvironment.
  2. Treat adaptive immune suppression: Administration of MemoryMune to activate dormant memory cells recognizing the tumor. Administration of LymphoBoost to repair deficient IL-12 production.
  3. Stimulation of immune response to cancer stem cells (StemVacs).
  4. Consolidation and maintenance of immunity: Cycles of StemVacs, supported by innaMune and LymphoBoost

 

NanoStilbene is an easily absorbed nanoemulsion of nanoparticle pterostilbene in the range of 75-100nm at a concentration of 30 milligrams per milliliter. The pterostilbene placed in a nanoemulsion droplet is free from air, light, and hard environment; therefore, as a delivery system, nanoemulsion can not only improve the bioavailability of pterostilbene but also protect it from oxidation and hydrolysis, while it possesses an ability of sustained release at the same time.

 

MemoryMune: This is a product derived from a two-step culture process of donor blood cells. The product MemoryMune reawakens dormant immune memory cells.  It is known that many cancer patients possess memory T cells that enter the tumor, however, once inside the tumor these cells are inactivated.  MemoryMune contains a unique combination of growth factors specific for immune system cells called “cytokines”.
LymphoBoost:  LymphoBoost is a proprietary formulation of Mifepristone, a drug approved for another indication, which we have shown to be capable of stimulating lymphocytes, particularly NK cells and T cells, both critical in maintaining anti-tumor immunity.
StemVacs is a platform for antigen-nonspecific immune modulatory treatment that can be utilized as a monotherapy or as a combination with antigen-specific modalities such as peptide or protein based vaccines. StemVacs is, therefore, a subcutaneously administered vaccine comprised of immune stimulatory peptides resembling cancer stem cell-specific proteins.
 innaMune:  This is a biological product derived from tissue culture of blood cells derived from healthy donors.  It is a combination of cytokines that maintain activity of the innate immune system cells, as well as having the ability to shift M2 macrophages to M1.